



2025 IMPACT REPORT

→ PELOTONIA®

The James

 THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER



1	INTRODUCTION
2	LEADERSHIP GRATITUDE
4	PELOTONIA 2025
16	INNOVATIVE INITIATIVES
24	OSUCCC – JAMES VISION
26	RESEARCH IMPACT
42	PELOTONIA THROUGH THE YEARS
44	ACKNOWLEDGMENTS

100%

OF EVERY PARTICIPANT-RAISED DOLLAR IS DIRECTED TO INNOVATIVE CANCER RESEARCH AT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER – ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE RESEARCH INSTITUTE (OSUCCC – JAMES).





Pelotonia's name is rooted in "peloton" — a group of cyclists who move faster and further together, joined by a shared vision. As Pelotonia completed its 17th year, we celebrate the power of community, working hand in hand to drive progress, achieving a record-breaking impact on accelerating cancer research.

In 2025, the spirit of coming together was unmistakable. Tens of thousands contributed their energy — participants, partners, supporters, and researchers — each vital in propelling us toward our One Goal. The collaboration between Pelotonia and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) remains the heartbeat of our initiative, uniquely fueling innovative research through community philanthropy and giving every action more impact on our mission than ever before.

This annual Impact Report is a testament to what's possible when community and science unite, showcasing the events and advancements made possible by community support and innovation. Through shared commitment and tireless effort, we are forging a cancer-free future where cancer research accelerates and outcomes improve. Together, we are Ending Cancer.

**THANK YOU FOR YOUR PASSION AND BELIEF IN
OUR MISSION THIS YEAR AND BEYOND.**



Dear Pelotonia Community,

As we reflect on our 17th year, I am filled with gratitude and awe for what the Pelotonia community accomplished in 2025. Together, we raised more than \$29.2 million for cancer research.

THIS YEAR WAS THE HIGHEST SINGLE-YEAR FUNDRAISING TOTAL IN OUR HISTORY — at a time when investment in cancer research is needed more than ever. Because of you, this community of Riders, Runners, Hikers, Challengers, Volunteers, partners, donors, and researchers, we are accelerating progress and strengthening the impact we can make for patients and families. Your energy, your effort, and your unwavering commitment to the Pelotonia mission continue to lift this movement.

This fundraising impact is incredible. What's even more exciting is what it represents. Every dollar raised signals belief in science. This investment is resulting in breakthroughs and more time with the people we love. Nearly 1,000 cancer Survivors joined the cause this year — the most ever in a single year.

Their participation is a powerful reminder of why this mission matters so deeply. They are Living Proof of the progress happening today.

This record year also reflects what makes Pelotonia so unique: community-driven momentum paired with world-class scientific partnership. Our long-standing relationship with the OSUCCC – James ensures that 100 percent of participant-raised funds accelerate innovative cancer research that leads to real, lifesaving impact. With Dr. Kim Rathmell now leading the OSUCCC – James as CEO, our collective efforts are poised to advance cancer discovery faster than ever before. Her leadership, vision, and belief in this community give us tremendous confidence in the breakthroughs on the horizon.

And yet, even as we celebrate this momentous year, the importance of our mission continues. Thank you for your generosity, your passion, and your belief in this work. You made 2025 an extraordinary year, one that will propel us forward as we strive for a future where every person who hears the words “you have cancer” gets more time, more hope, and more milestones with loved ones. That remains our goal.

We'll carry this momentum into 2026 with renewed determination and optimism to end cancer.

With profound thanks,



Joe Apgar
CHIEF EXECUTIVE OFFICER
PELOTONIA
—
Cancer Survivor

The James



At The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, our world-renowned cancer experts provide personalized, compassionate, relationship-based care to our patients and their families across the continuum of care.

With your help, we're developing innovative methods for cancer prevention, screening and treatment that are getting us closer to our shared vision of a cancer-free world.

WE ARE GRATEFUL THAT EVERY PELOTONIA PARTICIPANT-RAISED DOLLAR goes to cancer research at the OSUCCC – James. Your efforts are making an impact.



“Pelotonia is a powerful reminder of what we can accomplish together as a community. It’s inspiring to see how our shared commitment creates momentum to improve the lives of people with cancer. We deeply value Pelotonia’s partnership, which helps to fuel innovative breakthroughs and to advance our shared vision of creating a cancer-free world.”

JOHN J. WARNER, MD

CEO of The Ohio State University Wexner Medical Center
Executive Vice President at Ohio State



“Thank you to every Rider, Volunteer and Donor who made the 17th annual Pelotonia a record-breaking fundraising year. Your passion and purpose drive lifesaving research and treatments for all our patients. Pelotonia and the incredible community behind it embody the extraordinary spirit of the OSUCCC – James.”

W. KIMRYN RATHMELL, MD, PHD

CEO, The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

\$29,212,864

PELOTONIA 2025 FUNDRAISING TOTAL
NEW ALL-TIME RECORD

980



CANCER SURVIVORS – ALL-TIME RECORD

800



HIGH ROLLERS – ALL-TIME RECORD



7,249

RIDERS PEDALED
367,674
MILES



352

RUNNERS/HIKERS LOGGED
1,230
MILES



3,173

VOLUNTEERS SERVED
17,866
HOURS



1,824

CHALLENGERS COMPLETED
1,897
GOALS





12,003

TOTAL PARTICIPANTS



**PARTICIPANTS FROM
12 COUNTRIES**
(ACROSS 4 CONTINENTS)

Brazil	Israel
Canada	Singapore
China	Spain
Falkland Islands	Thailand
Germany	United States
Ireland	United Kingdom

235

**17-YEAR
PARTICIPANTS**

3,608

**FIRST-YEAR
PARTICIPANTS**

14-93

**RIDER AGE
RANGE**

387

PELOTONS

**PARTICIPANTS FROM
ACROSS 49 U.S. STATES**
(ALL EXCEPT ALASKA)

\$339,074,826

ALL-TIME PELOTONIA FUNDS RAISED SINCE 2009

for innovative cancer research at the OSUCCC – James



Watch the 2025 Number Reveal video here!

THE POWER OF COMMUNITY. FOR THE GREATER GOOD.

TOGETHER AS ONE



**IN 2025, THE PELOTONIA COMMUNITY UNITED
UNDER THE THEME TOGETHER AS ONE,**

advancing the evolved brand tagline introduced in 2024 that remains our singular mission: Ending Cancer. We accelerated the fight against cancer by empowering communities to boldly move forward for the greater good. As one, we inspired change. Together, we drove progress.

This theme celebrated the power of community and the collective impact of tens of thousands of people focused on a single purpose. By riding together,


rallying together, and fundraising together, we proved that we can achieve more than ever thought possible when we all focus on One Goal.

The 2025 arrow symbolized forward progress and ongoing momentum, leaving a mark much like the one this community has made since 2009. The tread design represented the shared journey we traveled and the impact made with every mile.

Together as One, we made 2025 our biggest year yet.



Watch the 2025 Launch video here!





OPENING CEREMONY

AUGUST 1, 2025




Opening Ceremony was a vibrant celebration of hope, unity, and progress, welcoming about 20,000 supporters to downtown Columbus to kick off Ride Weekend. The evening's stage program reflected this year's theme, emphasizing the strength of collective action. The Ohio State University President Ted Carter opened with heartfelt gratitude, recognizing the dedication of the community. Pelotonia CEO Joe Apgar shared an inspiring message affirming that progress is only possible when the community stands together. A special video message from Ohio State researchers led into the introduction of W. Kimryn Rathmell, MD, PhD, newly appointed CEO of the OSUCCC – James, who spoke about the vital partnership between science and community. Dr. Uma Borate, a Pelotonia-funded OSUCCC – James researcher, and cancer Survivor and First-Year Rider, Matt Wilson, spoke about the personal impact of Pelotonia's mission. The evening concluded with an energetic performance by platinum-selling rock band O.A.R., igniting the crowd and setting an inspiring tone for the rest of our signature weekend.



Watch the Opening Ceremony program here!





RIDE WEEKEND

AUGUST 2-3, 2025

Ride Weekend brought together thousands of Riders, Volunteers, and supporters for two days of cycling, connection, and celebration. From early morning starts to joyous finishes and picture-perfect late summer weather, the Pelotonia community came alive with energy and purpose. More than 7,200 Riders covered a wide range of routes from 24 miles to 190 miles, each pedal stroke driving progress toward lifesaving cancer research. Countless spectators lined the routes, cheering, waving signs, and offering encouragement that lifted spirits throughout the weekend. Behind the scenes, more than 3,000 Volunteers delivered essential support: managing logistics, maintaining bikes, providing refreshments, and passing out medals as Riders crossed the finish lines.



Watch the one-minute highlights video of Opening Ceremony and Ride Weekend!



CANCER → TOGETH

Bath&BodyWorks

Huntington

PEGGY & RICHARD
SANTULLI

VS&Co


The Jar
The Ohio State



GRAVEL DAY

OCTOBER 4, 2025

Gravel Day made a spectacular return in 2025, highlighted by the debut of the Trail Run/Hike. The weekend kicked off Friday night at Snow Fork Event Center in Nelsonville, Ohio, where more than 150 attendees enjoyed live music from the Hocking Hills Duo, food, drinks, and s'mores by the campfire. Many participants camped overnight in tents or RVs before Saturday's big event. More than 280 cyclists tackled 11-, 25-, and 48-mile gravel routes through Southeast Ohio's scenic hills, with climbs ranging from 900 to 4,200 feet in elevation gains. The first-ever Trail Run/Hike attracted more than 350 Runners and Hikers, who followed a 3.5-mile loop surrounded by scenic forests and streams, with flexible start times and optional additional laps. The day concluded with music, food, and finish line celebrations for all — powered by more than 200 Volunteers who made the third annual event possible.



Watch the highlights video of Gravel Day, including the new Trail Run/Hike!

2025

NIGHT OF IMPACT

NOVEMBER 18, 2025

Night of Impact is a celebration of the Pelotonia community's extraordinary fundraising efforts. More than 1,400 community members came together at KEMBA Live! for an evening of gratitude and excitement. Guests enjoyed food, music, and connection before hearing remarks from Pelotonia CEO Joe Apgar. Dr. Rathmell, CEO of the OSUCCC – James, then highlighted the growing momentum of Pelotonia-funded research and the innovation it continues to drive. The stage program recognized outstanding contributions across seven categories for the annual Pelotonia Awards and reflected on the community's collective achievements throughout the year. Attendees also heard stories of progress made possible by Pelotonia's investment in cancer research, reinforcing the impact of every single mile, dollar, and person. The evening culminated in an exciting video number reveal that filled the venue with energy to announce the highest single-year fundraising total in Pelotonia's history, \$29,212,864, bringing overall funds raised for innovative cancer research at the OSUCCC – James to more than \$339 million.



Watch the Night of Impact program here!





2025 PELOTONIA AWARDS

Each year, we honor individuals who have gone above and beyond in their support of our mission with the Pelotonia Awards. These members of the community are champions in the fight against cancer, embodying a relentless commitment to Ending Cancer. Their personal journeys are inspiring, and their extraordinary contributions deserve to be celebrated.

CONGRATULATIONS TO THE 2025 PELOTONIA AWARD RECIPIENTS!

FIRST-YEAR RIDER AWARD


The First-Year Rider Award recognizes a member of the Pelotonia community who brings newfound energy, excitement, and passion to recruitment, fundraising, and advancing our mission of Ending Cancer.



Lia Frost
Cardinal Health

PELOTONIA LEGACY AWARD

The Pelotonia Legacy Award recognizes an individual who has participated as a Rider, Challenger, or Volunteer for 10+ years and has exhibited unparalleled leadership and passion for the Pelotonia mission.




Dwight Hurd
Team 88

MARY HYATT COURAGE AWARDS

The Mary Hyatt Courage Award recognizes a cancer Survivor who embodies courage, perseverance, and grit and has been instrumental in advancing the Pelotonia mission through grassroots activism, leadership, fundraising, and volunteerism. This year, we honor two recipients with this well-deserved recognition.




Gordon Hecker
Team Bexley



Brandon Rader
Bath & Body Works

VOLUNTEER OF THE YEAR AWARDS

The Pelotonia Volunteer of the Year Award recognizes a Volunteer whose unselfish and dedicated service has made a significant difference in the Pelotonia community, while demonstrating a commitment to our collective One Goal. This year, we honor two recipients with this well-deserved recognition.



Jay Hobgood, PhD
Meteorology



Rachel Mauk, PhD
Meteorology

PELOTONIA-FUNDED RESEARCHER OF THE YEAR AWARD

The Pelotonia-Funded Researcher of the Year Award recognizes the outstanding achievements of a Pelotonia grant recipient. The award highlights the importance of career research funding and how support from the Pelotonia community is making a tangible difference in the work of researchers and the lives of patients.



Sameek Roychowdhury, MD, PhD
Team Buckeye – Sameek's Geeks

PELOTONIA KID OF THE YEAR AWARD

This award recognizes a Pelotonia Kids Rider whose spirit, enthusiasm, and commitment to fundraising inspire the entire community and showcase the power of the next generation in furthering our mission of Ending Cancer.



Nolan Wince
Pelotonia Kids – Team Huntington

COMMUNITY OF THE YEAR AWARD

The Community of the Year Award honors a local community that goes above and beyond in its support of Pelotonia. Through meaningful involvement across various individuals and groups, this community embodies the spirit and dedication that fuel our mission.



Village of Granville



Read about the awardees and other inspiring community stories on our blog!





LEAVING A LASTING IMPACT ON ENDING CANCER

THE PELTONIA LEGACY SOCIETY is a community of passionate changemakers who believe in a future without cancer.

Members share a deep commitment to advancing research and supporting our mission. Their generosity fuels the next wave of breakthroughs at the OSUCCC – James and carries the Pelotonia spirit forward for generations to come.

Consider joining these generous community members in their ongoing commitment to Ending Cancer by making a planned gift and becoming part of the Pelotonia Legacy Society.



“I chose to be a part of the Legacy Society to guarantee my support for Pelotonia and The James live on. My family was greatly supported by the men and women of The James through research and staff, and I want to make sure other families feel the same support and comfort we did.”

GISELA CHANG

17-Year participant & Pelotonia Legacy Society Member



“Cancer has impacted me, my family, and my friends in so many — too many — ways. After 17 years as a Pelotonia Rider and Volunteer, joining the Legacy Society is my way of continuing the positive momentum Pelotonia has created in advancing cancer research.”

BUD ABRAHAM

17-Year participant & Pelotonia Legacy Society Member



Learn how to pledge a legacy gift here!



IN COLLABORATION WITH



BENEFITING



In collaboration with the OSUCCC – James, 100% of every Pelotonia Kids participant-raised dollar is directed to innovative pediatric cancer research at Nationwide Children's Hospital.

Pelotonia Kids is a series of youth cycling events to engage the next generation of Pelotonia participants. Each event is uniquely local, planned by Pelotonia community members with support from Pelotonia. While each Pelotonia Kids ride varies in participant ages, route distances, and venue locations, the spirit remains the same: creating a fun, exciting experience for children to learn the joys of cycling and philanthropy.

In 2025, the number of Pelotonia Kids rides nearly doubled from the year prior with 11 total, raising more than \$167,000 for pediatric cancer research!



“Pelotonia Kids is a growing movement of young people stepping forward with hope and courage. The way these rides have expanded from 2024 to 2025 shows the strength of this community — more rides, more participation, and an even greater commitment to the mission. That upward momentum fuels our belief in what's possible and inspires the next generation to help end cancer for good.”

JOE APGAR
Chief Executive Officer, Pelotonia



“Nationwide Children's Hospital is honored to be a part of this program with Pelotonia, in collaboration with the OSUCCC – James. The passion and dedication of community volunteers to create an experience for Pelotonia Kids participants that is safe, fun, and meaningful is having a positive impact on the cutting-edge pediatric cancer research being conducted here in central Ohio. We are happy to see the next generation of philanthropists engaging in this worthy cause.”

STEVE TESTA
President, Nationwide Children's Hospital Foundation





KIDS RIDES IN 2025

- ➔ Pelotonia Kids – Rangers, Columbus: May 10
- ➔ Pelotonia Kids – Team Huntington, Columbus: May 17
- ➔ Pelotonia Kids – Stroll for Life, Plain City: June 7
- ➔ Pedal for Pancakes, Bexley: June 14
- ➔ Gears & Cheers, Lima: June 28
- ➔ Pelotonia Kids – Cincinnati: July 26
- ➔ SpokesKIDS, Granville: July 26
- ➔ SpokesKIDS Jr., Granville: July 26
- ➔ Biking with Brutus, Columbus: July 27
- ➔ Pelotonia Kids – Upper Arlington: August 23
- ➔ Pelotonia Kids – Linden: August 30



Watch the Pelotonia Kids recap videos here!



Huntington Bank

“

At Huntington, we believe in the power of partnership to drive purpose. By engaging with our vendors, we amplify the mission of Pelotonia — accelerating cancer research and bringing hope to countless lives. Just as these collaborations fuel impact, our colleagues embody that same spirit as Riders, Volunteers, and Challengers, showing what it means to move further, faster, together. This year, we were especially proud to launch our first Pelotonia Kids ride, inspiring the next generation to join in this mission of hope and discovery.”

ZACH WASSERMAN
Chief Financial Officer, Huntington Bank

HUNTINGTON ACHIEVES RECORD \$5 MILLION TO ACCELERATE CANCER RESEARCH

HUNTINGTON BANK reached a historic milestone in 2025, raising \$5,009,310, the largest annual total in the company's 17 years of supporting Pelotonia. Since 2010, when Huntington became one of Pelotonia's very first Major Funding Partners, the bank has helped fuel the organization's early growth and enduring momentum. This year's achievement underscores its deep, sustained commitment to the mission of Ending Cancer.

In 2025, Huntington mobilized more than 3,300 Peloton members from 31 U.S. states, including more than 1,700 Riders, 1,200 Volunteers, and 500 Challengers. Huntington continues to expand access by supporting Rider travel, activating colleagues across regions, and fostering a company culture where Pelotonia participation is both celebrated and encouraged.

Huntington also strengthened its innovative vendor engagement strategy. The 2025 Huntington Pelotonia Night of Impact Partner Event doubled in size and offered guests an immersive look at groundbreaking research in immuno-oncology and cellular therapy, deepening connection and driving increased support.

This year also marked the company's first-ever Pelotonia Kids event, where 295 young participants raised \$31,462 for pediatric cancer research at Nationwide Children's Hospital in collaboration with the OSUCCC – James.


With more than \$49 million raised for Pelotonia since 2009, Huntington continues to demonstrate the extraordinary impact of purpose-driven partnership.





→ 2025 HIGHLIGHTS

TEAM HUNTINGTON RALLIED MORE THAN 3,300 PARTICIPANTS FROM ACROSS 31 U.S. STATES TO RAISE \$5 MILLION



1,707
RIDERS

1,240
VOLUNTEERS

526
CHALLENGERS

206
SURVIVORS

137
HIGH ROLLERS



FUELING WOMEN-LED BREAKTHROUGHS IN RESEARCH FOR WOMEN'S CANCERS



THE VICTORIA'S SECRET GLOBAL FUND FOR WOMEN'S CANCERS accelerates innovation in cancer research for women, by women. In partnership with Pelotonia and scientific partner, the American Association for Cancer Research (AACR), this innovative initiative provides critical support to women scientists and clinicians across early, mid, and advanced career stages.

Since 2021, VS&Co. has invested more than \$13.5 million to advance prevention, early detection, diagnosis, and treatment of women's cancers, working to eliminate disparities and improve outcomes for all women. This initiative now supports women researchers across North America, Europe, Africa, and Asia, with grantees driving progress in breast, cervical, ovarian, and endometrial cancers.

In December of 2025, five Career Development Awards and three Rising Innovator Grants were awarded, bringing the total number of women scientists supported through the Victoria's Secret Global Fund to 33. Beyond funding, the initiative provides a space for peer community building, mentorship, professional development, and access to major scientific platforms that help build sustainable, long-term careers for women researchers.

The impact extends far beyond initial award funding: scientists supported by this initiative have generated more than \$29 million in external follow-on funding, 19 publications, 75 scientific presentations delivered at major meetings, and a patent.

→ 2025 HIGHLIGHTS

5 new Career Development Awards, including Xiaochen Zhang, MBBS, MPH, PhD, an Assistant Professor at The Ohio State University, bringing the total to 20 CDA awardees since 2022.

3 new Rising Innovator Grants, bringing the total to 8 RIG awardees.

250+ women researchers of all career levels attended the interactive professional development workshop at the AACR 2025 Annual Meeting.

Pictured:
Recipients of the 2024 Career Development Awards were honored at a reception during the AACR Annual Meeting in April 2025, joined by prior Global Fund awardees and representatives from VS&Co., Pelotonia, and AACR.



BRINGING INDUSTRY AND SCIENCE TOGETHER TO ACCELERATE INNOVATION

PELOTONIA ROUNDTABLE

“

The openness and collaboration fostered at Pelotonia Roundtable are crucial to advancing cancer research and care. It's not just about talking — it's about turning ideas into real-world treatments.”

PAUL WARD














Executive Director, U.S. Field Medical Oncology, Hematology, Medical Value, and Access, BeOne

PELOTONIA ROUNDTABLE serves as a collaborative platform uniting Pelotonia, the OSUCCC – James, and leaders across the pharmaceutical and biotech industries to accelerate progress in the cancer space. Since its launch in 2021, the event has transformed shared insights and scientific dialogue into meaningful action, deepening alignment around our collective mission to end cancer.

In 2025, the initiative saw a significant increase in engagement and partnership. Pelotonia welcomed 14 participating companies, up from 11 the year prior. More than 150 industry attendees and 120 OSUCCC – James physicians and researchers joined, making this the largest and most diverse group to date. The program fostered sustained, cross-sector conversations with OSUCCC – James researchers, clinicians, and leadership.

Participants engaged in individualized meetings and focused presentations offering insight into areas such as cancer prevention and survivorship, clinical trials infrastructure, pharmacy and clinical support, institutional development, and patient experience, including management of immune-related adverse events. These sessions highlighted how collaboration can accelerate discovery, advance clinical applications, and strengthen outcomes across cancer care.

Partnerships with these companies extend beyond the Roundtable. Many participate throughout the year by hosting fundraisers and growing their Pelotons. In addition, Roundtable partners help underwrite operational costs of the Pelotonia experience, ensuring that 100% of participant-raised funds continue to directly support innovative cancer research.

 AstraZeneca	 BeOne	 Boehringer Ingelheim	 Bristol Myers Squibb	 covermymeds®
 Daiichi-Sankyo	 DHL Supply Chain	 Genentech <small>A Member of the Roche Group</small>	 GILEAD Oncology	 Johnson & Johnson
 Lilly	 NOVARTIS	 Pfizer	 Takeda	



EXPANDING THE BLUEPRINT FOR IMPACT THROUGH INNOVATIVE PARTNERSHIP

THROUGH ITS BENEFIT HOME PROGRAM, M/I Homes has transformed what it does best — building homes — into a powerful engine for advancing innovative cancer research and inspiring others. To date, M/I Homes has now built 61 Pelotonia Benefit Homes and inspired numerous Riders, Volunteers, and Challengers to participate, raising more than \$13 million to support cancer research at the OSUCCC – James.

The M/I Homes Benefit Home Program began with a simple question in 2021: “How can we do more?” Recognizing that nearly everyone has a personal connection to cancer, M/I Homes rallied its partners across the country to donate labor, materials, and expertise. Proceeds from each Benefit Home

sale are then donated to Pelotonia for investing in innovative cancer research, turning every project into a collaboration of compassion and purpose.

Now active in 16 markets across nine states, the program raised more than \$3.5 million for innovative cancer research in 2025. With a strong foundation established, the M/I Homes Benefit Home Program continues to grow, bringing builders, homebuyers, and communities together in pursuit of One Goal.

Each new home stands as a testament to M/I Homes' expanding impact, the generosity of its partners, and the power of community-driven efforts toward a collective mission.

→ 2025 HIGHLIGHTS

The M/I Homes Benefit Home Program **raised more than \$3.5 million** for cancer research.

M/I Homes built and sold **16 Benefit Homes across 9 U.S. states**, including:

- Florida: Orlando, Sarasota, Tampa
- Illinois: Chicago
- Indiana: Indianapolis
- Michigan: Detroit
- Minnesota: Minneapolis
- North Carolina: Charlotte, Raleigh
- Ohio: Cincinnati, Columbus
- Tennessee: Nashville
- Texas: Austin, Dallas, Houston, San Antonio

Pictured:
M/I Homes Chicago team members and Pelotonia staff celebrate the completion of their M/I Homes Benefit Home in Chicago, Illinois.



LEADING WITH PURPOSE. FUELING POSSIBILITY.



→ 2025 HIGHLIGHTS

Nearly 1,000 RTRX attendees came from multiple industries including hospitality, healthcare, technology, private equity, nonprofit, design, legal, real estate, financial services, and retail.

Keynote speakers included John Hope Bryant with a call to unlock human potential; Sharon McMahon on principled leadership and constructive dialogue in complex times; Angus Fletcher on narrative intelligence; and LaVerne Council on building pathways for people and communities.

Workshop sessions led by industry experts focused on health, wellness, AI, and more.

The RTRX Super Peloton **raised nearly \$700,000**.

RTRX GATHERS PURPOSE-DRIVEN LEADERS

for an immersive experience rooted in connection, inspiration, and impact. Founded by Rockbridge in 2012 and fueled by a partnership with Pelotonia and the Columbus Partnership, RTRX blends professional and personal growth and a shared commitment to something greater, with proceeds supporting innovative cancer research at the OSUCCC – James.

Over four days filled with compelling conversations, engaging workshops, and inspiring speakers, RTRX 2025 aimed to challenge thinking, deepen relationships, and explore what's possible when leadership is grounded in purpose.

A powerful fireside chat between Dr. Rathmell, CEO of the OSUCCC – James, and Dr. Warner, CEO of The Ohio State University Wexner Medical Center, and Executive

Vice President at The Ohio State University, moderated by Pelotonia CEO Joe Apgar, explored the promise of discovery, Dr. Rathmell's vision after joining Ohio State from the National Cancer Institute, and the energy of Ride Weekend.

Two Pelotonia Funding Partners joined RTRX in 2025. DHL Supply Chain came on as an RTRX Funding Sponsor and Life Sciences Lead. In a conversation moderated by Pelotonia Vice Chair Doug Ulman, The Haslam 3 Foundation's Dee and Jimmy Haslam discussed building one of the largest family-owned businesses in America: Haslam Sports Group.

Through RTRX, Rockbridge has created an experience that inspires leaders to think bigger, connect deeper, and contribute to a future without cancer.







ENDING CANCER TOGETHER

THANK
YOU →

My research
is supported by
Pelotonia

THANK
YOU!
My research
is supported by
Pelotonia

My research
is supported by
Pelotonia

VS&C

VISION

By fueling research and innovation, you're helping to bring new treatments to the bedside faster – giving patients access to therapies that offer renewed hope. Your support empowers the talented scientists and innovative ideas behind these advances, making it possible to turn discoveries into life-changing care.

Thanks to the steadfast commitment of the Pelotonia community, we're able to pursue our shared vision of creating a cancer-free world.

The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER



Dear Pelotonia Community,

Participating in my first – and your 17th – Pelotonia this year was both an honor and a deeply moving experience.

The energy and inspiration of Opening Ceremony and Ride Weekend were unforgettable, and Gravel Day added yet another powerful dimension to this incredible movement. This extraordinary community, united with Ohio State's cancer program, is redefining possibilities in cancer research and patient care.

This impact report tells the story of that commitment. Within these pages, you'll see how your support fuels progress in seven key areas, each contributing to a larger story of innovation, collaboration and hope.

BECAUSE OF YOU:

- We recruit the brightest minds in cancer research
- We mentor the next generation of scientists and clinicians
- We invest in bold ideas that attract major grant funding
- We acquire cutting-edge technology to accelerate discovery
- We collaborate with statewide partners to improve outcomes
- We launch research initiatives that push boundaries
- We drive innovations that lead to life-changing treatments

The path to a cancer-free world is becoming clearer – because of you.

The OSUCCC – James is a powerhouse in the cancer landscape. Experiencing that power firsthand during Ride Weekend was an inspiring reminder of why we do this work – and of the shared vision that unites us.

To every Rider, Donor and Volunteer: thank you.

W. KIMRYN RATHMELL, MD, PhD

CEO, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Recruiting the brightest minds

The OSUCCC – James attracts the brightest minds in cancer research to Ohio State. We're honored to showcase a few of our recently recruited researchers.



IOANA BAIU, MD, MPH, joined Ohio State as a thoracic surgeon specializing in treating patients with cancer and other disorders of the lungs, esophagus and chest wall. Her research has been published in national and international peer-reviewed journals, and she serves as a reviewer for several prestigious publications, including *JAMA Network Open*, the *European Journal of Cardiothoracic Surgery* and the *Journal of Surgical Education*.

Dr. Baiu has presented her work at conferences around the country and is a member of the American College of Surgeons, the Society of Thoracic Surgeons and the American Association for Thoracic Surgery.

One of a small but growing number of women thoracic surgeons in the United States, Dr. Baiu is passionate about improving the outcomes of her patients, educating others about the importance of early detection of lung cancer and mentoring aspiring female surgeons.

We are excited to witness the impact Dr. Baiu will have on the OSUCCC – James in the years ahead.





JESSICA MERLIN, MD, PHD, MBA, is the director of the new Center for Research Excellence in Supportive Care (CREST) at the OSUCCC – James and professor of internal medicine with tenure in the Division of Palliative Medicine at The Ohio State University. She was recruited from the University of Pittsburgh Medical Center.

Dr. Merlin is an internationally renowned supportive care physician-scientist whose work focuses on the intersection of pain and substance use in individuals with serious illnesses, particularly cancer.

Under her leadership, the CREST team will conduct research that informs evidence-based clinical care, including clinical trials of pain and other symptoms management interventions in patients navigating cancer.

Dr. Merlin's arrival marks an exciting new chapter for supportive care research at the OSUCCC – James, and her leadership of CREST promises to elevate our clinical and scientific impact.



RECRUITMENT AND RETENTION

The James



TRIPARNA SEN, PHD, joined the Division of Medical Oncology as a professor, associate director of research and director of the Lung Cancer Therapeutic Platform. Dr. Sen is an internationally recognized leader in small cell lung cancer and tumor plasticity.

Dr. Sen brings deep expertise from prior roles at the Icahn School of Medicine at Mount Sinai and at Memorial Sloan Kettering Cancer Center. She was inducted into the Board of Directors of the International Association for the Study of Lung Cancer, the leading global authority on thoracic cancers.




TIMOTHY BURNS, MD, PHD, is a physician-scientist and medical oncologist at the OSUCCC – James specializing in treating thoracic malignancies such as non-small cell lung cancer and small cell lung cancer. Having lost both of his parents to lung cancer by the time he was 16 years old, he has a deep passion for his work and an understanding of what his patients and their families are going through.

His laboratory is focused on developing targeted therapies for oncogene-driven lung cancer and brain metastases.

Dr. Burns has served as principal investigator for multiple early-phase clinical trials to test novel agents and combinations for treating non-small cell lung cancer and was part of the team that developed sotorasib, the first U.S. Food and Drug Administration-approved medication that targets and inhibits the *KRAS G12C* gene mutation to fight non-small cell lung cancer.





RESEARCHER NAMED TO CITATION LAUREATES 2025 FOR NOBEL-CLASS RESEARCH

Recruited to Ohio State in 2024, **Glen Barber, PhD, FRS**, has been named as a Citation Laureate 2025 for his groundbreaking cancer research.

Dr. Barber, professor and director of the Center for Innate Immunity and Inflammation in the OSUCCC – James Pelotonia Institute for Immunology, is one of 22 researchers from around the world selected by experts at the Institute for Scientific Information at Clarivate Plc for pioneering contributions that are shaping the future of science and society. Since the program began, 83 Citation Laureates have gone on to receive Nobel Prizes, often years after their initial recognition by Clarivate.

Dr. Barber and his team study how the body's natural defenses fight viruses and cancer to uncover causes of infectious, inflammatory and cancer-related diseases. They also develop virus-based cancer treatments and explore ways to help reduce inflammation while supporting the body's immune response to cancer.



Learn more about these groundbreaking researchers and others who are helping to create a cancer-free world.



RECRUITMENT AND RETENTION

CURRENT (2025)

\$6,055,000 invested

SINCE 2010

The cancer program at Ohio State has recruited over **300 top scientists** with Pelotonia support.

Funding innovative ideas

Pelotonia-funded Idea Grants are research projects that help teams of faculty researchers at Ohio State gather early data for cutting-edge ideas. This program has allowed the OSUCCC – James to fund hundreds of faculty-led pilot research projects across 10 colleges at Ohio State and partner institutions.




STUDY REVEALS POSSIBLE PROTEIN TARGETS FOR LUNG CANCER TREATMENT

In what experts are calling a paradigm-shifting study, researchers at the OSUCCC – James have gained new insights about why the body's immune system T cells can fail, launching a new approach to immunotherapy treatment.

Zihai Li, MD, PhD, deputy director for translational research and founding director of the Pelotonia Institute for Immuno-Oncology (PIIO), led an investigation into why T cells, which are crucial for fighting infections and recognizing cancer, sometimes become “exhausted” and lose their effectiveness. His team's work revealed a hidden vulnerability in exhausted T cells: They are overwhelmed by misfolded proteins, which trigger a stress response that scientists hadn't noticed before. These landmark findings will guide scientists in targeting the protein-production and quality control cycle as a new avenue for treatment and are expected to have lasting impacts on the field.





UNDERSTANDING HOW THE IMMUNE SYSTEM REACTS TO CANCER

A Pelotonia Idea Grant is helping OSUCCC – James researchers stay at the forefront of immuno-oncology, a discipline that harnesses the body’s immune system to better combat cancer. Principal Investigator **Andrew Gunderson, PhD**, of the Translational Therapeutics Program, and his colleagues – including Co-Investigator **Susan Tsai, MD, MHS**, who was recruited to Ohio State with Pelotonia support in 2023 to direct the Division of Surgical Oncology – have identified certain immune cells that group together in cancer tumors. The clustering behavior of these cells may help people live longer, but scientists haven’t been sure how they work. This team hopes to uncover the origin of these clusters, what happens to the immune cells found in them post-surgery and how they might help the body harness its own power to stop cancer from recurring.

UNCOVERING NEW TARGETS FOR TREATING LUNG CANCER

Lung cancer is the leading cause of cancer death, and non-small cell lung cancer is by far the most common type. Pelotonia-funded research is helping to uncover the mechanisms that contribute to non-small cell lung cancer and suggest possible new targets for treating this deadly disease.

Vincenzo Coppola, MD, member of the Cancer Biology Program, and **Jacob Kaufman, MD, PhD**, member of the Translational Therapeutics Program, worked with an international team of scientists to investigate an understudied biochemical complex called CTLH. This process helps to control the cell lifecycle and may have implications for how cancers progress. The scientists found that two CTLH component proteins, *RANBP9* and *RANBP10*, regulate lung cancer cell growth and could be viable targets for intervention. Understanding cellular processes such as these is a crucial first step in developing future treatments.



IDEA GRANTS

CURRENT (2025)

7
new Pelotonia-funded Idea Grants worth
\$1,800,000

SINCE 2010

227
grants worth
\$35,876,000

Advancing new ways of prevention and diagnosis

Pelotonia dollars support the purchase of sophisticated equipment that helps scientists conduct cutting-edge cancer research. Some of this equipment is for the OSUCCC – James Shared Resources, which provide specialized services to assist cancer researchers.

PELOTONIA-SUPPORTED EQUIPMENT PURCHASES PROVIDE VITAL ASSISTANCE IN CANCER STUDIES

In 2023, Pelotonia dollars supported the acquisition of a 10X Genomics CytAssist for the Genomics Shared Resource and the Comparative and Digital Imaging Shared Resource. This instrument, which helps transfer genetic information in tissue samples from standard to high-definition slides, has produced excellent data for several scientists.

Esmerina Tili, PhD, and her colleagues used CytAssist to analyze genetic changes linked to therapy resistance in two rare tumor types: chordoma and olfactory neuroblastoma. By studying how different cell populations evolve within tumors as cancer advances, they found new mechanisms of tumor progression, identified additional cell types and learned how immune therapies can be directed to help the body's T cells kill tumor cells.

Andrew Gunderson, PhD, says the CytAssist has been critical in helping his team study the relationships among normal and cancer cells within pancreatic tumors. Their experiments often require preliminary detailed pathological evaluation of each patient's tumor. The CytAssist aids this evaluation by orienting slices of biologic tissue just as the researchers want them to be, an invaluable technique that would be impossible without this instrument.





ADVANCING METHODS OF PREVENTION AND DIAGNOSIS

The OSUCCC – James allocates Pelotonia funds to statewide initiatives that promote early detection and better outcomes for patients with colorectal, uterine, lung and breast cancer in Ohio.

In 2025, \$435,000 was allocated to these initiatives, including funds for Beating Lung Cancer in Ohio (BLCIO), a statewide effort led by lung cancer specialists **Peter Shields, MD**, and **David Carbone, MD, PhD**, that is designed to improve survival and quality of life for patients newly diagnosed with advanced (stage IV) non-small cell lung cancer. BLCIO is an OSUCCC – James resource that involves many investigators who are accruing patients and conducting research.

Primary objectives are to assess survival with next-generation gene sequencing (with co-factors such as stress), and gauge quality of life and psychological determinants as predictors for patient outcomes. To date, BLCIO has enrolled nearly 500 patients, including 75% from the OSUCCC – James and 25% from 12 community hospitals across 68 of Ohio's 88 counties.

Participants agree to monthly telephone interviews for 10 months and then every other month until the end of the second year. They also allow access to their medical records and imaging, and they agree to provide blood and tumor samples for a biorepository.

Findings from this work have led to 15 research publications in scientific journals and 18 scientific presentations.



ADVANCING NEW WAYS OF PREVENTION AND DIAGNOSIS

CURRENT (2025)

\$564,000

for equipment and new technologies

\$435,000

for statewide initiatives

Delivering new therapies that give hope

Pelotonia dollars support OSUCCC – James initiatives such as the Drug Development Institute, the Center for Cancer Engineering, the Center for Prevention and Survivorship and the Clinical Trials Office. These strategic research investments are helping OSUCCC – James researchers make a difference.

OHIO STATE DISCOVERS BREAKTHROUGH DRUG TO HELP MORE CANCER PATIENTS

In last year's impact report, we reported that an oral drug called JBZ-001 was discovered and developed at Ohio State for treating patients with solid tumors or non-Hodgkin lymphoma. In an exciting update, JBZ-001 will soon also be offered in a clinical trial to patients who have a deadly subtype of acute myeloid leukemia (AML).

Progress on JBZ-001

The drug was originally called HOSU-53 when it was being developed over several years with funding support from Pelotonia. It targets cancer by stopping a key enzyme called dihydroorotate dehydrogenase that helps cancer grow and spread.

JBZ-001 was approved by the FDA as an investigational new drug for treating solid-tumor or non-Hodgkin lymphoma patients who have few or no remaining options. That phase I clinical trial, led by **Asrar Alahmadi, MD**, opened at the OSUCCC – James in March of 2025.

As of mid-November 2025, five patients at the OSUCCC – James had been enrolled in the trial at varying dose levels, including patients with rare cancers such as thymoma, cervical cancer, uterine sarcoma and small cell lung cancer. So far, the treatment has been well tolerated with no concerning safety signals at multiple dose levels. The trial is currently enrolling to the third dose level in the dose-escalation part. Additionally, the team expanded the outreach to include a community early-phase trial site to improve patient access.

Next steps: Expanding to AML patients

In 2026, researchers at the OSUCCC – James, University of Cincinnati and University of Pittsburgh will study JBZ-001 in a first-in-human phase I clinical trial involving patients with a deadly AML subtype.

The new clinical trial will be led by **Alice Mims, MD**, and **Christopher Coss, PhD**, from the OSUCCC – James, along with project leader John C. Byrd, MD, of the University of Pittsburgh, and Erin Hertlein, PhD, of the University of Cincinnati.



After finishing this trial, the researchers will conduct a second-phase trial in which JBZ-001 will be given in combination with another drug, called decitabine, to untreated patients who have the AML subtype. At the completion of this work, they will have moved JBZ-001 to the clinic and established an informed dose for these AML patients.

Breakthroughs in cancer treatment are the results of tireless research, rigorous testing and sustained funding. Because of your commitment to Pelotonia, scientists can pursue bold ideas and patients can access promising clinical trials, receive innovative therapies and live fuller lives.



Learn more about this landmark drug and others who are helping to create a cancer-free world.



“Many of the same physicians and scientists who built the case for JBZ-001 to be approved as an investigational new drug will also play a role in this new clinical trial to establish a safe and effective dose for patients with AML.”

CHRISTOPHER COZZ, PHD

Molecular Carcinogenesis and Chemoprevention Program
at the OSUCCC – James

PELOTONIA DOLLARS HELP CLINICAL TRIALS OFFICE FACILITATE STUDIES OF NEW TREATMENTS

In 2025, the OSUCCC – James allocated \$871,000 in Pelotonia funding to the Clinical Trials Office (CTO), a centralized resource that helps researchers develop, implement and manage innovative studies that offer the latest cancer treatments, some of which are available nowhere else.

CTO staff work closely with the principal investigator of each clinical trial to ensure compliance to protocol-specific procedures. The CTO offers complete protocol management, including patient screening, visit coordination, reporting adverse reactions among patients, regulatory submissions and data management.

Led by OSUCCC Associate Director for Clinical Research **William Carson, MD**, and CTO Medical Director **John Hays, MD, PhD**, the CTO operates in collaboration with the OSUCCC – James Clinical Scientific Review Committee, which plays a vital role in protocol review and monitoring to ensure that all clinical trials are scientifically sound, reach patient enrollment goals and demonstrate medical progress.

CTO Senior Director **Angela Campbell, MS**, reports that more than 650 clinical trials are available at the OSUCCC – James and that approximately 12% of James patients are enrolled in a trial, which is well above the national average and places Ohio State's cancer program at the forefront of offering tomorrow's treatments today.



Learn more about the Clinical Trials Office.



STRATEGIC RESEARCH INVESTMENTS

CURRENT (2025)

\$6,328,000 invested

\$817,000 invested in the Center for Cancer Prevention and Survivorship and the Center for Cancer Engineering

CLINICAL TRIALS OFFICE:

650+ clinical trials are available at the OSUCCC – James

Approximately 12% of James patients are enrolled in a trial

Inspiring the next generation of cancer researchers

The OSUCCC – James annually awards \$2 million in Pelotonia funds to train the next generation of cancer researchers. The awards are issued to Ohio State students in any discipline or level who want to conduct cancer research in the labs of faculty mentors.



SCHOLAR SPOTLIGHT: MADILYNN YANO

Madilynn Yano is an Ohio State senior studying biology, and she was selected along with 21 other undergraduate, graduate, postdoctoral and medical students as a 2025 Pelotonia Scholar.

Yano is paired with mentor **Rosa Lapalombella, PhD**, co-leader of the Leukemia and Hematologic Malignancies program at the OSUCCC – James. Together, they're studying how certain DNA mutations affect the outcome of chronic lymphocytic leukemia – a type of cancer that affects white blood cells.

"I'm learning and researching while I'm helping people further the whole field of medicine," Yano says. "I couldn't do it without Pelotonia and the guidance I've received at The James at Ohio State."

After graduation, she plans to go to medical school and continue working in a laboratory while also treating pediatric patients.

"I couldn't see myself doing anything else," she says.



SCHOLAR SPOTLIGHT: HANNAH HYLTON-MCCOMAS

For students like Hannah Hylton-McComas, becoming a Pelotonia Scholar can serve as a critical first step on a path to professionalization that ultimately leads to a successful career in cancer research. In 2021, Hylton-McComas was an undergraduate student at Ohio State, pursuing a degree in pre-med biology. She was awarded an undergraduate Pelotonia Scholarship to conduct cancer genetics research in the lab of mentor **Ruben Petreaca, PhD**.

“Dr. Petreaca was the best mentor I could have asked for,” she says. “He encouraged me to put forth my best work.”

Hylton-McComas’ work paid off. Today, she is a PhD candidate specializing in genetics, genomics and cancer biology in the Biomedical Sciences Graduate Program at Ohio State.

“Since I’m passionate about genetics and invested in cancer research, graduate school was the next natural step for me,” Hylton-McComas says. “I decided to go for my PhD in biomedical sciences because it provides an outlet for me to serve others while exploring questions that remain unanswered.”

As a Pelotonia graduate scholar, her work focuses on understanding treatment resistance mechanisms in small cell lung cancer and DNA damage repair pathways. She also has a passion for undergraduate biological education, advocating for rural outreach STEM programs and active learning.



COLLIER AWARDED SECOND ANNUAL MASON FISHER GRANT

Katharine Collier, MD, assistant professor in the Division of Medical Oncology and member of the Translational Therapeutics Program at the OSUCCC – James, is the second recipient of the annual Mason Fisher Grant, a research award funded entirely by Pelotonia dollars.

This program provides early-career faculty members or learners in Ohio State’s College of Medicine or the OSUCCC – James with up to \$50,000 to advance their research of genetic mutations that can lead to cancer.

Dr. Collier’s project will help scientists better understand the genetic underpinnings of urothelial carcinoma, the most common type of bladder cancer. By germline genetic testing 500 patients, Dr. Collier hopes to learn how a patient’s inherited mutations can influence their response to different cancer treatments. The aim is to be able to use genetic testing to select the most effective, individualized treatment for every patient.

Established in 2023, this grant honors Ohio State medical student Mason Fisher. Fisher was a three-time Pelotonia Rider who aspired to become a cancer surgeon-scientist prior to his tragic passing in 2022. This program was established to celebrate his remarkable life and inspire others to pursue cancer research as passionately as he did.



PELOTONIA SCHOLARS PROGRAM

CURRENT (2025)

\$2,556,000

awarded for 22 scholarships

THOSE SCHOLARS INCLUDE

13 undergraduate students

6 graduate students

2 postdoctoral researchers

1 medical student

SINCE 2010

734 scholarships awarded to students from 53 countries and 36 U.S. states

Transforming cancer care

In its first six years, the Pelotonia Institute for Immuno-Oncology (PIIO) – established in 2019 through an initial pledge of \$102 million from the Pelotonia community – has recruited 37 top-tier faculty researchers, bringing the total number of PIIO faculty to 135 scientists who drive breakthroughs in immuno-oncology, a discipline that harnesses the body's immune system to combat cancer.

NATIONAL COLLABORATION DEEPENS SCIENTIFIC UNDERSTANDING OF LEUKEMIA

A team of researchers at the OSUCCC – James' PIIO collaborated with scientists at Memorial Sloan Kettering (MSK) Cancer Center in New York to investigate how genetic mutations can lead to acute myeloid leukemia, a type of blood cancer that starts in the bone marrow.

Led by first author Pu Zhang, PhD, a former Pelotonia Scholar who is now a postdoctoral fellow at MSK, this study identified that mutations in the *TET2* and *TP53* genes are drivers of this type of leukemia, paving the way for new therapeutic strategies to help patients overcome the disease. Co-corresponding authors for this study, which was supported in part by Pelotonia funds, were **Rosa Lapalombella, PhD**, co-leader of the Leukemia and Hematologic Malignancies (LHM) Program at the OSUCCC – James, and LHM Program member **Bradley Blaser, MD, PhD**.

NEW FIRST-IN-HUMAN CLINICAL TRIAL FOR GLIOBLASTOMA PATIENTS

With FDA approval of a new immunotherapy treatment, there's new hope for patients diagnosed with glioblastoma. As the most aggressive form of brain cancer, glioblastoma has historically had few treatment options. Lead investigator **Zihai Li, MD, PhD**, founding director of the PIIO, and **Bradley Elder, MD**, are working to change that.

The team is assessing the safety and feasibility of a breakthrough therapy that targets a key regulator of immune suppression in tumors. Thirty patients with recurrent high-grade gliomas, or tumors of the brain and spinal cord, will receive the investigational new drug during this phase I clinical trial.



PD-1 BLOCKADE PROVES EFFECTIVE FOR INOPERABLE MELANOMA IN PHASE II TRIAL

Results from a phase II clinical trial by SWOG, an NCI-supported cancer clinical trials group, show that single-agent anti-PD-1 immunotherapy delivers unusually high response rates in patients with inoperable desmoplastic melanoma – a rare skin cancer that is highly responsive to immune-based treatments.

Led in part by **Kari Kendra, MD, PhD**, at the OSUCCC – James, Antoni Ribas, MD, of UCLA, and colleagues, the study establishes PD-1 blockade as the preferred first-line therapy for these patients, providing the strongest clinical evidence to date that supports PD-1 immunotherapy as a standard of care. The findings also reveal key biological differences that may shape future precision treatment strategies.

CANCER DISABLES A KEY PROTEIN IN WHITE BLOOD CELLS TO EVADE IMMUNE ATTACK

In an important advance for tumor immunology, researchers led by **Stanley Huang, PhD**, of the Translational Therapeutics Program at the OSUCCC – James, **Haoxin Zhao, PhD**, a postdoctoral researcher at Ohio State, and colleagues discovered that cancer cells suppress a critical mitochondrial chaperone system (key proteins) within macrophages – white blood cells of the immune system that orchestrate antitumor responses.

This disruption “blinds” macrophages to danger signals and enables tumors to grow unchecked. By exposing this previously hidden mechanism of immune evasion, the study opens new avenues for therapies to restore mitochondrial quality-control pathways in macrophages, potentially strengthening the immune system’s ability to recognize and destroy cancer.



FIRST-OF-ITS-KIND, NATIONWIDE, DECENTRALIZED THERAPEUTIC TRIAL FOR PANCREATIC CANCER

For people with aggressive or advanced cancers, traveling to gain access to novel therapies in clinical trials is difficult and not possible for most. OSUCCC – James researchers are the first to overcome this barrier and reimagine clinical trial possibilities for patients everywhere.

Ohio State recently launched a first-of-its-kind, nationwide, decentralized clinical trial conducted entirely by telehealth to test how well an oral targeted therapy drug works in treating adults with a certain form of advanced pancreatic cancer. Patients do not have to travel; therapy is shipped directly to their homes and care is coordinated with their local oncologist.

Led by **Sameek Roychowdhury, MD, PhD**, this new trial combines the power of genomic-driven treatment with the accessibility of telehealth. By connecting patients remotely with cancer experts and cutting-edge clinical research, Dr. Roychowdhury’s team is breaking down geographic and logistical barriers that often prevent people from receiving advanced cancer care.

A longtime Rider and multiple Pelotonia Idea Grant awardee, Dr. Roychowdhury was honored as the 2025 Pelotonia-Funded Researcher of the Year.



PELOTONIA INSTITUTE FOR IMMUNO-ONCOLOGY

CURRENT (2025)

\$8,684,000 invested

13 new members

7 new recruits

40 new grants

SINCE 2019

**135 members were awarded
\$33,066,000 in grant funding**

322 peer-reviewed articles

**296 immunotherapy clinical
trials launched**

The James




The Pelotonia partnership has enabled the OSUCCC – James to strategically invest in key areas that lead to groundbreaking discoveries, more effective treatments and improved patient outcomes.

2025 OSUCCC – JAMES CANCER RESEARCH INVESTMENTS

From the fundraising of the 2024 Pelotonia campaign

Pelotonia's 100% model ensures all fundraising dollars support cancer research. Pelotonia funds raised in 2024 are spent in 2025 on research projects. Investment amounts vary slightly from the Pelotonia campaign total due to the timing of research fund allocation.




Numbers are rounded to the nearest thousand dollar.



OSUCCC – JAMES CANCER RESEARCH INVESTMENTS SINCE INCEPTION

From the fundraising of all Pelotonia campaigns through 2024

Pelotonia's 100% model ensures all fundraising dollars support cancer research. Research investments since inception represent Pelotonia funds raised through 2024. Investment amounts vary slightly from the Pelotonia campaign total due to the timing of research fund allocation.



Numbers are rounded to the nearest thousand dollar.

Thank you for
strengthening
discovery.
We will create
a cancer-free
world together.

→ PELOTONIA®
OVER 17 YEARS...

40,017
RIDERS, RUNNERS, & HIKERS

25,168
VOLUNTEERS

44,677 AND
CHALLENGERS

798,881
DONORS

— HAVE RAISED —

\$339,074,826

FOR INNOVATIVE CANCER RESEARCH AT

The James



→ PELOTONIA ANNUAL FUNDRAISING TOTALS



2009

FUNDRAISING TOTAL
\$4,511,868



2010

FUNDRAISING TOTAL
\$7,846,705



2011

FUNDRAISING TOTAL
\$13,108,639



2012

FUNDRAISING TOTAL
\$16,871,403



2013

FUNDRAISING TOTAL
\$19,007,104



2014

FUNDRAISING TOTAL
\$21,049,621



2015

FUNDRAISING TOTAL
\$23,659,675



2016

FUNDRAISING TOTAL
\$24,104,423



2017

FUNDRAISING TOTAL
\$26,229,637



2018

FUNDRAISING TOTAL
\$27,400,779



2019

FUNDRAISING TOTAL
\$23,233,696



2020

FUNDRAISING TOTAL
\$10,502,362



2021

FUNDRAISING TOTAL
\$19,313,532



2022

FUNDRAISING TOTAL
\$21,815,484



2023

FUNDRAISING TOTAL
\$25,006,939



2024

FUNDRAISING TOTAL
\$26,200,095



2025

FUNDRAISING TOTAL
\$29,212,864

AKNOWLEDGMENTS

PELOTONIA BOARD



Robert H. Schottenstein
BOARD CHAIR
CHAIRMAN & CEO
M/I Homes, Inc.



Doug Ulman
VICE CHAIR
FOUNDER
Orli



Renee Cacchillo
PRESIDENT & CEO
Safelite Group



Victor Crawford
BOARD MEMBER
The Hershey Company



Cindy Hilsheimer
MANAGING PRINCIPAL
BeecherHill



Raphael E. Pollock, MD, PhD, FACS
DIRECTOR
OSUCCC



W. Kimryn Rathmell, MD, PhD
CEO
OSUCCC – James



Daniel Rosenthal
PRESIDENT & CEO
Global Critical Logistics



Steve Steinour
CHAIRMAN, PRESIDENT & CEO
Huntington Bancshares Inc.



Abigail Wexner
CEO
Whitebarn Associates

PELOTONIA TEAM



Joe Apgar
CEO



Carolyn Appelhans
COMMUNITY ENGAGEMENT
DIRECTOR



Jess Audley
TECHNOLOGY SERVICES
MANAGER



Megan Bush
GRAPHIC DESIGN
COORDINATOR



Emily Cantwell
GIFT PROCESSING
MANAGER



Nick Denby
CFO



Ashley Ellashek
MERCHANDISING
SPECIALIST



Lauren Graham
EVENT OPERATIONS
DIRECTOR



Callan Hash
EXECUTIVE
ADMINISTRATOR



Grace Jenkins
GIFT PROCESSING
COORDINATOR



Eric Olsavsky
VP, COMMUNITY ENGAGEMENT
& PARTNERSHIPS



Maddie Parisi
EVENT & VOLUNTEER
OPERATIONS COORDINATOR



Hannah Rose
COMMUNITY ENGAGEMENT
COORDINATOR



Rebecca Shortman
MARKETING &
COMMUNICATIONS MANAGER



Brandon Simpauco
COMMUNITY PROGRAMS
MANAGER



Alexa Waldron
PARTNERSHIP EXPERIENCE
COORDINATOR



Erika Walker
PHILANTHROPY &
STEWARDSHIP MANAGER



Katie Wilson
MARKETING &
COMMUNICATIONS DIRECTOR



→ PELOTONIA

THANKS TO OUR GENEROUS FUNDING PARTNERS, PELOTONIA IS ABLE TO DIRECT 100% OF EVERY PARTICIPANT-RAISED DOLLAR TO INNOVATIVE CANCER RESEARCH AT THE OSUCCC – JAMES.

BENEFITING

The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

MAJOR FUNDING PARTNERS



Bath&BodyWorks®



PEGGY & RICHARD
SANTULLI

VS&Co
VICTORIA'S SECRET & CO.

SUPPORTING FUNDING PARTNERS



THE
HASLAM³
FOUNDATION



Safelite

NOTABLE FUNDING PARTNERS



DIAMOND HILL



MAKE AN IMPACT. SAVE LIVES.

Join the Pelotonia community to accelerate innovative cancer
research at the OSUCCC – James.



REGISTER OR DONATE AT [PELOTONIA.ORG](https://pelotonia.org)



The James



THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER